Future Fund LLC Purchases 11,988 Shares of Globus Medical, Inc. $GMED

Future Fund LLC lifted its position in Globus Medical, Inc. (NYSE:GMED) by 41.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,011 shares of the medical device company’s stock after buying an additional 11,988 shares during the period. Globus Medical makes up about 1.2% of Future Fund LLC’s portfolio, making the stock its 18th largest position. Future Fund LLC’s holdings in Globus Medical were worth $3,581,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. boosted its stake in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Advisory Services Network LLC acquired a new position in Globus Medical in the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Larson Financial Group LLC boosted its stake in Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after purchasing an additional 242 shares during the period. Finally, Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Barclays upped their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wells Fargo & Company reduced their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Truist Financial set a $115.00 price objective on shares of Globus Medical in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $82.00 on Friday. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The company has a market capitalization of $11.13 billion, a P/E ratio of 19.07, a price-to-earnings-growth ratio of 1.70 and a beta of 1.00. The company has a 50-day simple moving average of $87.01 and a 200 day simple moving average of $88.41.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% on a year-over-year basis. During the same period last year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.